Hemorrhagic Stroke Risk: Tenecteplase vs Alteplase in NIHSS 5
In patients with acute ischemic stroke and NIHSS score of 5, tenecteplase and alteplase carry similar risks of symptomatic intracranial hemorrhage, with no clinically significant difference between the two agents.
Evidence Summary
The most recent and comprehensive evidence demonstrates equivalent hemorrhagic safety profiles between these thrombolytics:
Symptomatic Intracranial Hemorrhage (sICH) Risk
The 2024 AcT trial post-hoc analysis specifically examined patients with NIHSS ≤5 and found no significant difference in sICH rates: 2.9% with tenecteplase (0.25 mg/kg) versus 3.3% with alteplase (adjusted RR 0.79,95% CI 0.24-2.54) 1. This represents the highest quality evidence directly addressing your question in the minor stroke population.
Supporting Meta-Analyses
Multiple recent meta-analyses corroborate these findings:
2025 meta-analysis found no significant difference in sICH: 3.09% with tenecteplase vs 2.49% with alteplase (RR 1.21,95% CI 0.92-1.59; p=0.18) 2
2023 systematic review examining complications specifically reported comparable sICH risk (RR 0.89,95% CI 0.65-1.23) 3
2024 meta-analysis confirmed no difference in sICH (OR 1.12,95% CI 0.79-1.59) 4
Dose-Specific Considerations
Critical caveat: The hemorrhagic risk profile varies by tenecteplase dose:
- 0.25 mg/kg dose (recommended): sICH risk 1.69% (95% CI 1.14-2.32%) 3
- 0.4 mg/kg dose: sICH risk 4.19% (95% CI 1.92-7.11%) - significantly higher 3
The 2018 AHA/ASA guidelines note that tenecteplase 0.4 mg/kg "might be considered" for minor strokes without major vessel occlusion, but this was based on limited data 5. Current evidence strongly favors the 0.25 mg/kg dose for optimal safety-efficacy balance.
Guideline Perspective
The 2018 AHA/ASA guidelines state that tenecteplase 0.4 mg/kg "has not been proven to be superior or noninferior to alteplase" and note it "appears to be similarly safe" 5. The guidelines specifically mention the largest trial (1100 subjects) showed "similar safety and efficacy profile" in patients with median NIHSS of 4 5.
Clinical Bottom Line
For your patient with NIHSS 5:
- Neither agent carries higher hemorrhagic risk when comparing tenecteplase 0.25 mg/kg to standard-dose alteplase
- Absolute sICH risk is low with both agents (approximately 2-3%)
- Tenecteplase offers practical advantages: single bolus administration versus 60-minute infusion
- Avoid tenecteplase 0.4 mg/kg in routine practice due to higher hemorrhagic risk without proven benefit
Common Pitfalls
Do not assume dose equivalence: The 0.4 mg/kg tenecteplase dose shows numerically higher hemorrhagic complications. Stick with 0.25 mg/kg if choosing tenecteplase 3.
Minor stroke does not mean minor risk: Even with NIHSS 5, both agents carry 2-3% sICH risk. The decision to treat should still weigh individual hemorrhagic risk factors (age, imaging findings, anticoagulation history) 5.